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Abstract: KRAS mutation has been unambiguously identified as a marker of resistance to 
cetuximab-based  treatment  in  metastatic  colorectal  cancer  (mCRC)  patients.  However, 
most  studies  of  KRAS  mutation  analysis  have  been  performed  using  homogenously 
archived  CRC  specimens,  and  studies  that  compare  freshly  frozen  specimens  and  
formalin-fixed paraffin-embedded (FFPE) specimens of CRC are lacking. The aim of the 
present study was to evaluate the impact of tissue preservation on the determination of 
KRAS mutational status. A series of 131 mCRC fresh-frozen tissues were first analyzed 
using both high-resolution melting (HRM) and direct sequencing. KRAS mutations were 
found in 47/131 (35.8%) using both approaches. Out of the 47 samples that were positive 
for KRAS mutations, 33 had available matched FFPE specimens. Using HRM, 2/33 (6%) 
demonstrated suboptimal template amplification, and 2/33 (6%) expressed an erroneous 
wild-type  KRAS  profile.  Using  direct  sequencing,  6/33  (18.1%)  displayed  a  wild-type 
KRAS status, and 3/33 (9.1%) showed discordant mutations. Finally, the detection of KRAS 
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mutations was lower among the FFPE samples compared with the freshly frozen samples, 
demonstrating that tissue processing clearly impacts the accuracy of KRAS genotyping. 
Keywords: genotyping; KRAS; fixative 
 
1. Introduction  
Over  the  past  decade,  with  the  introduction  of  new  cancer  drugs  such  as  targeted  agents,  the 
treatment of metastatic colorectal cancer (mCRC) has greatly improved. The epidermal growth factor 
receptor  (EGFR)  is  a  key  molecular  player  in  cell  growth  and  survival.  This  receptor  is  often 
overexpressed in mCRC and contributes to cancer progression through the modulation of biological 
events, such as proliferation, adhesion and angiogenesis. Monoclonal antibodies such as cetuximab 
prevent ligand-induced EGFR activation and the subsequent induction of signal transduction pathways, 
thus  disrupting  downstream  signaling,  adhesion,  and  angiogenetic  pathways.  Cetuximab  has  been 
shown to be clinically effective in phase II trials for treating irinotecan-refractory mCRC patients who 
present positive EGFR expression [1,2]. Recent randomized phase III clinical trials have also shown 
that cetuximab has significant clinical activity when administered in combination with irinotecan as a 
first- or second-line agent [3]. A significant proportion of EGFR-positive mCRC patients, however, are 
resistant to anti-EGFR treatments. No more than 23% of mCRC patients respond to the combination 
treatment of cetuximab and irinotecan, and less than 10% respond to anti-EGFR monotherapy [4,5]. 
One reason for this difference is that other pathways may also be activated downstream of EGFR 
because of a mutation in the KRAS oncogene [6,7]. KRAS gene mutations at codons 12 (wild-type 
GGT) and 13 (wild-type GGC) have been shown to be predictive of the response to cetuximab in 
mCRC  [8]  and  to  behave  as  independent  prognostic  factors  in  advanced  mCRC  with  cetuximab 
treatment [6]. 
For ethical and economic reasons, it is necessary to better define the subpopulation of patients who 
would truly benefit from cetuximab through KRAS mutation analysis. Beyond the available molecular 
methodology (i.e., High Resolution Melting (HRM) or direct sequencing), the optimal consideration 
for routine identifying KRAS mutations is in the tissue source. Fresh-frozen tissue represents an ideal 
supply of archival material for molecular investigations but is not usually possible in routine practice. 
Formalin-fixed  paraffin-embedded  (FFPE)  tissues  undergo  effective  preservation  of  the  cellular, 
architectural,  and morphological  details  and allow easy storage at  room temperature for extensive 
periods. For these reasons, this processing has become the principal method for archiving tissues to 
determine  KRAS  status.  However,  FFPE  processing  impairs  the  extraction  efficacy  and  quality  of 
DNA, thus preventing the ability to conduct high-quality molecular analyses and potentially affecting 
the results of the KRAS analysis [9–17]. The main objective of this study was to examine whether 
KRAS genotyping on FFPE CRC specimens give comparable results with freshly frozen specimens 
simultaneously obtained from the same patient. To meet this objective, we compared the KRAS status 
between the paired freshly frozen and FFPE tissue samples using both a screening and a diagnostic 
PCR-based method. Int. J. Mol. Sci. 2011, 12                     
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2. Results and Discussion 
First, we retrospectively analyzed mutations in exon 2 of KRAS in a series of 131 frozen mCRC 
tumor  samples  using  HRM  analysis.  The  genomic  yield  of  DNA  obtained  from  the  frozen  tissue 
samples was 798.9 ±  826.9 µg/mL. PCR inhibition was not observed for any of the samples, and 
therefore, PCR was completed for all of the tested DNA samples. Starting with 25 ng of genomic DNA 
as a template, the mean threshold cycle value (Ct) was 21.79 ±  1.62 (range: 19.68–28.85). The melting 
curve  obtained  for  the  84-bp  amplicon  was  monophasic  (Figure  1A),  which  suggested  only  one 
homogeneous melting domain and allowed a reliable distinction of mutated samples. In particular, for 
47 (35.8%) specimens of the series, a distinct shape of the curves on normalized difference plots was 
observed, and the corresponding curve patterns for the HRM difference plots unambiguously revealed 
the HRM-positive samples. The difference plots for exon 2 of KRAS in 7 HRM mutation-positive 
(related  to  p.G12A,  p.G12C,  p.G12S,  p.G12D,  p.G12V,  p.G13C  and  p.G13D)  and  3  HRM  
mutation-negative samples are shown in Figure 1B.  
Figure  1.  High-resolution  melting  (HRM)  analysis  of  exon  2  of  KRAS  in  10  DNA 
specimens  from  frozen  samples.  (A) Normalized  high-resolution  melting  curves.  PCR 
products were labeled with an intercalating dye, and the fluorescence signal was plotted as 
the temperature increased; (B) The difference plot displays the melting curve of each tested 
sample  subtracted  from  the  reference  curve  obtained  by  analyzing  a  control  wild-type 
KRAS sequence. 
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Exon 2 of KRAS was analyzed in the same 131 samples by direct sequencing. Long (245 bp) DNA 
fragments were successfully amplified from all of the frozen samples. The HRM-determined status of 
exon 2 of KRAS was confirmed by direct sequencing for all of the samples. Eleven different KRAS 
mutations were observed among the 47 HRM-positive samples, with p.G12D, p.G12V and p.G13D 
representing the most frequent substitutions at frequencies of 31.9%, 27.7%, and 17%, respectively 
(Table  1).  In  addition,  one  sample  exhibited  a  double  point  mutation  that  combined  the  p.G12V 
alteration with a silent mutation in codon 13. As expected, all of the HRM-negative samples carried 
the wild-type sequence of exon 2 of KRAS.  
Table 1. Mutations in exon 2 of KRAS detected by HRM and sequencing in fresh-frozen samples. 
Nucleotide Change  Amino Acid Change  Number of Cases 
c.34G>A  p.G12S  2 
c.34G>C  p.G12R  1 
c.34G>T  p.G12C  1 
c.35_36GT>TC  p.G12V  1 
c.35G>A  p.G12D  15 
c.35G>C  p.G12A  3 
c.35G>T  p.G12V  13 
c.37G>C  p.G13R  1 
c.37G>T  p.G13C  1 
c.38G>A  p.G13D  8 
c.40G>A  p.V14I  1 
Total     47 
Among the 84 frozen DNA samples considered to have wild-type KRAS by direct sequencing and 
HRM, 68 matched FFPE samples with more than 30% tumor cells were available. Using HRM, all of 
these samples showed the wild-type KRAS genotype. Except for four samples that were not amplified, 
all  of  these  samples  showed  the  wild-type  KRAS  genotype  using  direct  sequencing.  Among  the  
47 frozen DNA samples considered to have KRAS mutation by direct sequencing and HRM, only  
33 matched FFPE samples with more than 30% of tumor content were available. A high yield of DNA 
(722.6 ±  406 µg/mL) was obtained, and no substantial differences in the yield of DNA were observed 
compared  with  that  of  the  frozen  tissue  samples.  For  the  HRM  analysis,  a  shift  toward  higher 
quantification cycle (Cq) values (mean: 29.54 ±  1.3) and a larger Cq range (25.4–31.95) were observed 
for the FFPE specimens compared with the frozen specimens. Two of 33 (6%) tested genomic DNA 
samples  demonstrated  an  ineffective  amplification  (Cq  >  33).  Both  the  normalized  curves  and 
difference plots showed a profile similar to that observed with wild-type KRAS for two others (6%) 
specimens (Figure 2), resulting in a total of 4/33 (12.2%) discordant results between the paired frozen 
and FFPE samples (Table 2).  
In the direct sequencing, the 245-bp PCR product was successfully amplified in only 27/33 (81.8%) 
cases. Given that the rate of successful PCR amplifications is known to be at least partially related to 
the size of the product [14,18–20], we designed a new set of primers to reanalyze exon 2 of KRAS. By 
reducing  the  size  of  the  amplified  DNA  fragment  from  245  bp  to  164  bp,  the  success  rate  was 
increased to 31/33 (94%) (Table 2). Among them, 6/33 (18.1%) exhibited a wild-type KRAS status, Int. J. Mol. Sci. 2011, 12                     
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and 3/6 were also found to have a wild-type status or were not amplified with HRM, demonstrating 
that direct sequencing is a less sensitive method for mutation detection (Table 2). Notably, when we 
compared the type of nucleotide changes in the mutated KRAS between the paired frozen samples and 
FFPE  specimens,  discordant  nucleic  alterations  were  discovered  in  3/33  (9.1%)  samples  (G12V, 
G12D, and G12V in frozen and G13C, G12V, and G12D in paired FFPE samples, n°  8, 29, and 127, 
respectively) (Figure 3). Finally, in one case (n°  131) that had a double mutation 35_36GT > TC, 
direct sequencing was able to detect the nucleotide change, unlike HRM, which exhibited a wild-type 
profile for that case. 
Figure 2. The HRM profiles of frozen tissue samples and their matched FFPE samples.  
(A) The HRM profiles of three mutated KRAS frozen samples (S8, S28, and S13) and three 
wild-type KRAS frozen samples (C1, C2, and C3) are shown; (B) The HRM profiles of S8, 
S28, S13, C1, C2, and C3 matched FFPE samples are shown. 
 
Table 2. Genotyping of exon 2 of KRAS in paired frozen and FFPE samples using HRM 
and direct sequencing. 
Sample 
no. 
Frozen 
 
  FFPE  
  Direct sequencing  HRM      Direct sequencing  HRM 
 
Nucleotide 
change 
Amino acid 
change 
  
  Visual 
PCR band  
Nucleotide 
change 
Amino acid 
change 
  
                 
8  c.35G>T  G12V  mutation    +  c.37G>T  G13C  mutation 
11  c.35G>T  G12V  mutation    +  c.35G>T  G12V  mutation 
13  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation Int. J. Mol. Sci. 2011, 12                     
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Table 2. Cont. 
18  c.34G>C  G12A  mutation    -   -   NA  mutation 
21  c.35G>A  G12D  mutation    -   -   NA  mutation 
24  c.35G>T  G12V  mutation    +  c.35G>T  G12V  mutation 
25  c.35G>T  G12V  mutation    +   -   WT  NA 
28  c.38G>A  G13D  mutation    +   -   WT  WT 
29  c.35G>A  G12D  mutation    +  c.35G>T  G12V  mutation 
32  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
36  c.35G>A  G12D  mutation    +   -   WT  mutation 
38  c.34G>T  G12C  mutation    +   -   WT  mutation 
42  c.35G>T  G12V  mutation    +  c.35G>T  G12V  mutation 
43  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
65  c.34G>A  G12S  mutation    +  c.34G>A  G12S  mutation 
68  c.38G>A  G13D  mutation    +  c.38G>A  G13D   mutation 
74  c.38G>A  G13D  mutation    +   -   WT  mutation 
79  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
80  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
84  c.35G>T  G12V  mutation    +  c.35G>T  G12V  mutation 
91  c.35G>T  G12V  mutation    +  c.35G>T  G12V  mutation 
96  c.37G>T  G13C  mutation    +   -   WT  NA 
98  c.38G>A  G13D  mutation    +  c.38G>A  G13D   mutation 
106  c.38G>A  G13D  mutation    +  c.38G>A  G13D   mutation 
107  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
110  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
115  c.35G>T  G12V  mutation    +  c.35G>T  G12V  mutation 
118  c.35G>T  G12V  mutation    +  c.35G>T  G12V  mutation 
122  c.34G>C  G12A  mutation    +  c.34G>C  G12A  mutation 
125  c.35_36GT>TC  G12V  mutation    +  c.35_36GT>TC  G12V  WT 
127  c.35G>T  G12V  mutation    +  c.35G>A  G12D  mutation 
129  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
131  c.35G>A  G12D  mutation    +  c.35G>A  G12D  mutation 
WT, wild-type; NA, not amplified; 164 bp PCR product of a primer produced a visual band in the 
electrophoresis gel; -, no visual band was detected. 
The  potential  benefit  of  KRAS  status  determination  in  mCRC  is  clear.  Patients  without  KRAS 
mutations in codons 12 and 13 exhibit a significant antitumor response in a treatment regimen that 
includes cetuximab compared with patients who are not treated with cetuximab [21]. Therefore, the 
U.S. Food and Drug Administration and the European Medicines Agency have mandated that the 
mutational  status  of  KRAS  be  determined  prior  to  anti-EGFR  treatment.  However,  no  standard 
recommendations  have been proposed for the management of CRC specimens  that will allow the 
determination of KRAS status.  Int. J. Mol. Sci. 2011, 12                     
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Figure 3. Discordant electropherograms of exon 2 of KRAS obtained by direct sequencing 
between  3  paired  frozen  and  FFPE  specimens.  The  upper  panel  shows  the 
electropherograms  obtained  for  frozen  samples  8  (A),  29  (B),  and  127  (C)  using  the 
forward (upper) and reverse  (bottom) primers.  The bottom  panel  shows  the discordant 
nucleotide alterations observed in the matched FFPE specimens. 
 
The impact of specimen processes and storage on the accuracy of HRM and direct sequencing of 
KRAS,  to  our  knowledge,  has  never  been  systematically  investigated.  Some  previous  studies 
determined KRAS and EGFR genotypes in both paraffin-embedded and frozen tissues [14,18,22–26]. 
However, most studies used specimens from different patients and do not compare the same tissue 
sample divided into two parts [22–26]. Thus, the same tumor materials may not be available, making 
genotype comparisons difficult. In our study, 131 tissue samples were processed under freshly frozen 
and FFPE conditions in parallel. With an average KRAS mutation frequency of 35.8% in the frozen 
tissues,  our  results  were  consistent  with  previously  published  reports  [8,21,27,28].  In  these  
mutation-positive specimens, the genotype determined using HRM and direct sequencing was fully 
concordant,  demonstrating  that  HRM  remained  a  confident  screening  strategy  for  KRAS  mutation 
detection, as recently reported in several studies [10,13,17,22,29–33]. Importantly, although attention 
was paid to avoid false-negative results caused by amplification of normal cells by including only 
specimens  with  more  than  30%  tumor  cells,  6%  of  the  FFPE  samples  were  considered  
mutation-positive in the matched frozen samples that were identified as wild-type by HRM. This value 
was higher using direct sequencing. The relatively high degree of false-negative detection may be 
explained  by  the  low  sensitivity  of  both  methods,  particularly  direct  sequencing,  to  detect  DNA 
variation. No correlation was observed between the FFPE and matched frozen samples with regard to 
the percentage of tumor cells, which was estimated to be between 30% and 90% in the analyzed 
samples. However, this absence of correlation can certainly also be attributed to the direct impact of 
tissue processing on the accuracy of KRAS genotyping. Finally, Figure 3 showed discrepant KRAS 
nucleotide changes in three samples due to the conservation process. However, these changes did not Int. J. Mol. Sci. 2011, 12                     
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modify  the  KRAS  genotype  interpretation.  Indeed,  the  tumor  was  still  mutation-positive,  and  the 
patient in both cases was ineligible for treatment with anti-EGFR antibodies. 
Evaluation of the degree of DNA degradation (preservation) is of major importance when handling 
FFPE samples; otherwise, real-time PCR and sequencing results may not be interpreted appropriately. 
In our study, we performed a 2% agarose gel electrophoresis to check the DNA degradation level in 
each sample. As expected, the frozen samples were not degraded, whereas the FFPE samples were 
partially  fragmented. However,  when we checked for PCR product  amplifications,  we observed a 
correct amplification in both the FFPE and frozen tissues, demonstrating that our PCR conditions were 
adapted to the FFPE samples. We showed examples of DNA fragmentation (Figure 4A) and KRAS 
164-bp  PCR  products  (Figure  4B)  in  3  FFPE  and  matched  frozen  samples  with  discrepant  
nucleotide changes.  
Figure  4.  DNA (A) and KRAS 164-bp PCR products  (B)  run on 2%  agarose  gel  for 
samples 8, 29, and 127 frozen of fixed in formaldehyde. Non-degraded DNA exhibited 
bands  of  high  molecular  weight.  DNA  extracted  from  blood  samples  were  used  as  a 
positive control. MW: molecular weight. F: frozen samples. P: FFPE samples. 
A
B
MW F P F P F P
MW F P F P F P
150 bp
 
Several studies have investigated the sample quality requirements of FFPE tissues for sequencing 
approaches [14,16,34,35]. Interestingly, Miyamae and collaborators adapted the Smart Amplification 
Process  version  2  to  rapidly  detect  EGFR  and  KRAS  mutations  in  DNA  extracted  from  FFPE  
tissues [14]. That study clearly demonstrated that this procedure could identify mutations with high 
accuracy and gave a reliable diagnostic result based exclusively on amplification [14]. In addition, 
Troncone and collaborators also proposed options for testing the degree of FFPE DNA preservation 
and amplification capacity, such as the inclusion of internal controls within qPCR reactions. In cases Int. J. Mol. Sci. 2011, 12                     
 
 
3199 
where  specimens  are  not  available,  KRAS  testing  may  be  reliably  performed  on  cytological  
specimens [16].  
In our series, we observed that direct sequencing revealed novel nucleotide changes in three FFPE 
samples compared with their respective frozen samples (Table 2). Using the same molecular assay, 
Marchetti  et  al.  found  45  artifactual  mutations  in  exons  18  through  21  of  the  EGFR  gene  from  
10  independent  PCR  amplification  products  of  70  lung  cancer  FFPE  sections  [36].  The  authors 
demonstrated that artifactual C > T/G > A or A > G/T > C transitions, which we also observed in our 
study, appeared in the DNA isolated from paraffin-embedded tissue samples. These artifacts were 
ascribed  to  postmortem  deamination  of  cytosine  or  adenine  to  uracil  or  hypoxanthine  residues, 
respectively. Recently,  Gallegos  Ruiz  et  al. compared  EGFR  mutations  in  47 non-small cell lung 
cancer samples in frozen and paraffin-embedded specimens [18] and detected significant nucleotide 
changes in FFPE samples, not in frozen specimens. Overall, these results provide evidence for the 
influence  of  fixation  and  embedding  procedures  on  the  appearance  of  artifactual  mutations  or  
false-negative results. It is likely that deamination does not occur uniformly throughout the tumor, but 
at  different  sites.  However, we did  not  check the possible intra-tumor heterogeneity of this  DNA 
modification by performing DNA sequencing at multiples sites. This issue should be considered a 
limitation of our study. Formalin has been used for decades as the most abundant supply of archival 
material  for  tumor  diagnosis  and  staging  via  light  microscopic  evaluation.  However,  the  current 
practice of specimen preparation is diverse and lacks strict standardization (thickness of tissue, volume 
of  fixative,  time  of  fixation)  or  well-defined  standard  operating  procedures  [37].  Accordingly, 
incomplete tissue fixation or tissue overfixation introduces  significant sources of variability in the 
yield  and  quality  of  the  nucleic  acids  that  are  extracted,  resulting  in  suboptimal  molecular  
analysis [38]. Although frozen tissue is the gold standard for molecular analyses, its use in pathological 
laboratories is impractical because of the associated expense and technical difficulty.  
3. Experimental Section  
3.1. Tissue Samples and Processing 
CRC tissue samples (n = 131) were obtained surgically between 2006 and 2009 and were handled 
by the Department of Pathology (Montpellier, France). The institutional review board approved all of 
the protocols. To assess the feasibility of detecting KRAS mutations in both freshly frozen and FFPE 
tissues,  the  tissue  samples  were  cut  into  two  equal  parts.  One  of  the  halves  was  immediately  
snap-frozen in liquid nitrogen and stored at −80 ° C until DNA extraction. The other half was processed 
for  formalin  fixation  and  paraffin  embedding  using  a  TissueTek  VIP  automated  processor  (Bayer 
HealthCare Diagnosis Division). From the FFPE and frozen tissues, 7-µm-thick sections were cut and 
pooled into a 1.5-mL tube. A pathologist estimated the percentage of tumor cells for both the FFPE 
and frozen tissue sections.  
3.2. DNA Isolation 
All of the DNA was extracted using the DNA QIAamp DNA Extraction Kit (Qiagen) following the 
manufacturer’s instructions. For the FFPE tissues, the sections were dewaxed, followed by extraction Int. J. Mol. Sci. 2011, 12                     
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in 100% xylene and washing with 100% ethanol. The samples are air-dried before DNA extraction. 
The  extracted  DNA  was  quantified  using  a  NanoDrop  ND-1000  Spectrophotometer  (Nanodrop 
Technologies). The DNA integrity was assessed using 2% agarose gel electrophoresis. 
3.3. PCR Amplification and DNA Sequencing 
Two  specific  sets  of  oligonucleotide  primers  were  used  to  determine  the  status  of  the  
mutations in exon 2 of KRAS in both the FFPE and frozen tissue sections. Set 1 (long fragment,  
245  bp)  included  the  forward  and  reverse  primers  5′-GTACTGGTGGAGTATTTGAT-3’  
and  5′-GTCCTGCACCAGTAATATGC-3′,  respectively.  Set  2  (short  fragment,  164  bp)  
corresponded  to  the  forward  and  reverse  primers  5′-AAGGCCTGCTGAAAATGACTG-3′  and  
5′-GTCCTGCACCAGTAATATGC-3′,  respectively.  Amplification  was  performed  in  a  volume  of 
50 μL containing 1×  PCR buffer, 250 µM deoxyribonucleoside triphosphate (dNTP), 0.4 µM of each 
forward  and  reverse  primer,  5  units  of  AmpliTaq  Gold
®  DNA  Polymerase  (Applied  Biosystems, 
Courtaboeuf, France), and 200 ng of genomic DNA. The thermal cycling conditions included a 10-min 
denaturation step at 94 ° C, 40 cycles of 94 ° C for 30 s, 60 ° C for 30 s and 72 ° C for 1 min, and a final 
extension  at  72  ° C  for  7  min.  The  PCR  products  were  run  on  an  agarose  gel  and  purified  by 
exonuclease I digestion (Amersham Biosciences) and shrimp alkaline phosphatase (Roche Applied 
Sciences),  according  to  the  manufacturer’s  instructions.  Direct  sequencing  of  the  amplicons  was 
performed with both the forward and the reverse primers using the BigDye
TM Terminator v3.1 Cycle 
Sequencing Kit with the ABI PRISM
TM 3100 Genetic Analyzer (Applied Biosystems). The mutations 
were confirmed by sequencing independent PCR products of DNA derived from tumor cells. All of the 
samples were analyzed in duplicate.  
3.4. HRM Analysis 
For the HRM screening, an 84-bp fragment from exon 2 of KRAS was PCR amplified using a 
Rotor-Gene 6000™ instrument (Qiagen) and the LightCycler 480 High Resolution Melting Master 
Reaction  Mix  (Roche  Diagnostics).  Each  20-μL  reaction  volume  comprised  of  25  ng  purified  
genomic  DNA,  10  μL  reaction  mix,  3.0  mmol/L  MgCl2  and  0.25  μmol/L  of  each  forward 
(5′GGCCTGCTGAAAATGACTGAA3′)  and  reverse  (5′AATTAGCTGTATCGTCAAGGCACTC3′) 
primer. The cycling conditions were as follows: 95 ° C for 5 min, followed by 50 cycles of 95 ° C for  
15 s, 63 ° C for 25 s with an initial 11 cycles of touchdown (0.5 ° C/cycle), and 72 ° C for 25 s. The 
melting conditions included one cycle of 95 ° C for 1 min, one cycle of 40 ° C for 1 min and one cycle 
of 65 ° C for 2 s, followed by a melt from 65 ° C to 95 ° C that increased 0.1 ° C per second. All of the 
samples  were tested in  duplicate. The HRM  data were analyzed using  Rotor-Gene 6000 software 
(v1.7).  For  each  sample,  the  normalized  melting  curves  were  evaluated,  and  these  samples  were 
compared with the wild-type sample controls in a deduced difference plot. Significant deviations from 
the horizontal line relative to the spread of the wild-type controls were indicative of sequence changes 
within the analyzed amplicon. The samples with distinct melting curves compared with the wild-type 
allele were recorded as positive mutations. Int. J. Mol. Sci. 2011, 12                     
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4. Conclusions 
KRAS mutation is currently used to guide the clinical
 management of mCRC. Extreme caution must 
be taken when genotyping small amounts of DNA, especially if the DNA samples have been extracted
 
from paraffin. In this study, we showed that the magnitude of agreement for the mutational status of 
KRAS between frozen and matched FFPE specimens was low, with suboptimal template amplifications 
and an erroneous wild-type genotype, regardless of the molecular method used. In addition, artifactual 
mutations in codons 12 and 13 of the KRAS gene from independent PCR amplification
 products were 
found to be associated with formalin specimen preservation. Finally, frozen specimen archiving is 
preferential where possible. When only FFPE samples are available, the risk of artifacts should be 
prevented  by  using  large  amounts  of  template  DNA  or  by  performing  multiple  amplifications. 
Alternatively, specimens may be fixed with both non-formalin and formalin fixatives. 
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